Succinic Acid Tert-Butyl Ester Diethylcarbamoylmethyl Ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Succinic Acid Tert-Butyl Ester Diethylcarbamoylmethyl Ester
• 英文别名: 4-O-tert-butyl 1-O-[2-(diethylamino)-2-oxoethyl] butanedioate
• 化学式: C₁₄H₂₅NO₅
• 分子量: 287.35
• InChiKey: WFNXTKIRNUKDNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N,N-二乙基-2-氯乙酰胺 、 单叔丁基琥珀酸酯 、 Dicaesio carbonate 在 碘化钠 氮气 、 水 、 silica gel 、 Isohexane ethyl acetate 作用下， 以 N,N-二甲基甲酰胺 、 乙酸乙酯 为溶剂， 反应 3.0h， 以to afford the title compound (3.29 g) as a clear oil的产率得到Succinic Acid Tert-Butyl Ester Diethylcarbamoylmethyl Ester
  参考文献：
  名称：

  PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION

  摘要：

  本文揭示了一种单或二琥珀酸酯化合物，其中琥珀酸核中的一个或两个酸基以生物活性的基团形式得到保护，并且使用该化合物来增强线粒体功能。该化合物可以是式（I）的形式，其中R1为H或可选择取代的烷基或式（II）的基团，R2独立地是式（II）定义的基团，其中式（II）如本文所定义。

  公开号：

  US20150259317A1

文献信息

• Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation
  申请人：NEUROVIVE PHARMACEUTICAL AB

  公开号：US10307389B2

  公开（公告）日：2019-06-04

  The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.

  本发明涉及一种用于治疗或预防乳酸中毒的琥珀酸原药。
• Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation
  申请人：NEUROVIVE PHARMACEUTICAL AB

  公开号：US20170100359A1

  公开（公告）日：2017-04-13

  The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.
• Prodrugs of Succinic Acid for Increasing ATP Production
  申请人：NEUROVIVE PHARMACEUTICAL AB

  公开号：US20170105960A1

  公开（公告）日：2017-04-20

  The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
• US9670175B2
  申请人：——

  公开号：US9670175B2

  公开（公告）日：2017-06-06
• [EN] PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION<br/>[FR] SUCCINATES PROTÉGÉS POUR ACCROÎTRE LA PRODUCTION MITOCHONDRIALE D'ATP
  申请人：MITOPHARM LTD

  公开号：WO2014053857A1

  公开（公告）日：2014-04-10

  Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.